Cited by 349Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies

Lambert, Mary P., Viola, Kirsten L., Chromy, Brett A., Chang, Lei, Morgan, Todd E., Yu, Jiaxin, Venton, Duane L., Krafft, Grant A., Finch, Caleb E., Klein, William L.·2001·Journal of Neurochemistry

DOI 10.1046/j.1471-4159.2001.00592.x

Open this paper in CoChat — free account

Abstract

In recent studies of transgenic models of Alzheimer's disease (AD), it has been reported that antibodies to aged beta amyloid peptide 1-42 (Abeta(1-42)) solutions (mixtures of Abeta monomers, oligomers and amyloid fibrils) cause conspicuous reduction of amyloid plaques and neurological improvement. In some cases, however, neurological improvement has been independent of obvious plaque reduction, and it has been suggested that immunization might neutralize soluble, non-fibrillar forms of Abeta. It is now known that Abeta toxicity resides not only in fibrils, but also in soluble protofibrils and oligomers. The current study has investigated the immune response to low doses of Abeta(1-42) oligomers and the characteristics of the antibodies they induce. Rabbits that were injected with Abeta(1-42) solutions containing only monomers and oligomers produced antibodies that preferentially bound to assembled forms of Abeta in immunoblots and in physiological solutions. The antibodies have proven useful for assays that can detect inhibitors of oligomer formation, for immunofluorescence localization of cell-attached oligomers to receptor-like puncta, and for immunoblots that show the presence of SDS-stable oligomers in Alzheimer's brain tissue. The antibodies, moreover, were found to neutralize the toxicity of soluble oligomers in cell culture. Results support the hypothesis that immunizations of transgenic mice derive therapeutic benefit from the immuno-neutralization of soluble Abeta-derived toxins. Analogous immuno-neutralization of oligomers in humans may be a key in AD vaccines.

Integrity signals

Registry

Crossref · 10.1046/j.1471-4159.2001.00592.x

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citation
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
High-Level Neuronal Expression of Aβ1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
MODELS OF AMYLOID SEEDING IN ALZHEIMER'S DISEASE AND SCRAPIE: Mechanistic Truths and Physiological Consequences of the Time-Dependent Solubility of Amyloid Proteins
Harper, J. D., & Lansbury, P. T. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.385 · Cited by 1,652
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,506
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state
Pike, C., Burdick, D., Walencewicz, A., Glabe, C., & Cotman, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-04-01676.1993 · Cited by 1,417
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.
Lorenzo, A., & Yankner, B. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12243 · Cited by 1,324

Show all 45 references

Research works printed but not linked: 5

Guerette P. A., 2000, Oligomeric Aβ in PBS‐soluble extracts of human Alzheimer brain, Socneurosci. Abstract., 25, 2129
Kim K. S., 1990, Quantitation of amyloid β‐protein with two monoclonal antibodies, Neurosci. Res. Commun, 7, 113
Klein W. L., 2001, Molecular Mechanisms of Neurodegenerative Diseases, 1
Stine W. B., 2000, Amyloid beta 1–40 and 1–42: solubilization parameters and structural outcomes, Soc. Neurosci. Abstract., 26, 800
Terry R. D., 1999, Alzheimer Disease

Sorted by citations

Items 101–200 of 349

Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease
Gao, C. M., Yam, A. Y., Wang, X., Magdangal, E., Salisbury, C., Peretz, D., Zuckermann, R. N., Connolly, M. D., Hansson, O., Minthon, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015725 · Cited by 105
“However, recent reports suggest that smaller, soluble Ab oligomers are more likely to be the pathogenic agents of disease [3,4,7–10].”
Background
Aβ Oligomers Dysregulate Calcium Homeostasis by Mechanosensitive Activation of AMPA and NMDA Receptors
Fani, G., Mannini, B., Vecchi, G., Cascella, R., Cecchi, C., Dobson, C. M., Vendruscolo, M., & Chiti, F. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00811 · Cited by 106
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification
Izzo, N. J., Yuede, C. M., LaBarbera, K. M., Limegrover, C. S., Rehak, C., Yurko, R., Waybright, L., Look, G., Rishton, G., Safferstein, H., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12302 · Cited by 95
Immunotherapy for Alzheimer's disease
Dodel, R. C., Hampel, H. J., & Du, Y. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00349-1 · Cited by 102
Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers
Kim, K., Lee, C. H., & Park, C. B. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00107d · Cited by 101
An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies
Ryan, D. A., Narrow, W. C., Federoff, H. J., & Bowers, W. J. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.05.001 · Cited by 102
Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease
Fukuchi, K.-I., Tahara, K., Kim, H., Maxwell, J. A., Lewis, T. L., Accavitti-Loper, M. A., Kim, H., Ponnazhagan, S., & Lalonde, R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.012 · Cited by 100
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97
A neurodegenerative cellular stress response linked to dark microglia and toxic lipid secretion
Flury, A. G., Aljayousi, L., Park, H.-J., Khakpour, M., Mechler, J., Aziz, S., McGrath, J. D., Deme, P., Sandberg, C., Ibáñez, F. G., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.11.018 · Cited by 102
Why Alzheimer's is a disease of memory: The attack on synapses by Aß oligomers (ADDLs)
Viola, K. L., Velasco, P. T., & Klein, W. L. (2008) · The journal of nutrition health & aging · doi:10.1007/bf02982587 · Cited by 97
Self-citation
A Ganglioside-induced Toxic Soluble Aβ Assembly
Yamamoto, N., Matsubara, E., Maeda, S., Minagawa, H., Takashima, A., Maruyama, W., Michikawa, M., & Yanagisawa, K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606202200 · Cited by 96
Mice as models: Transgenic approaches and Alzheimer's disease
Games, D., Buttini, M., Kobayashi, D. T., Schenk, D., & Seubert, P. A. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s316 · Cited by 93
Aβ-dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer’s disease
Leshchyns’ka, I., Liew, H. T., Shepherd, C. E., Halliday, G. M., Stevens, C. H., Ke, Y. D., Ittner, L. M., & Sytnyk, V. (2015) · Nature Communications · doi:10.1038/ncomms9836 · Cited by 94
Autoantibodies to Redox-modified Oligomeric Aβ Are Attenuated in the Plasma of Alzheimer's Disease Patients
Moir, R. D., Tseitlin, K. A., Soscia, S. J., Hyman, B. T., Irizarry, M. C., & Tanzi, R. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414176200 · Cited by 88
In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques
Poduslo, J. F., Ramakrishnan, M., Holasek, S. S., Ramı́rez-Alvarado, M., Kandimalla, K. K., Gilles, E. J., Curran, G. L., & Wengenack, T. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04591.x · Cited by 91
TDP-43 Inclusion Bodies Formed in Bacteria Are Structurally Amorphous, Non-Amyloid and Inherently Toxic to Neuroblastoma Cells
Capitini, C., Conti, S., Perni, M., Guidi, F., Cascella, R., Poli, A. D., Penco, A., Relini, A., Cecchi, C., & Chiti, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086720 · Cited by 88
Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro
Cascella, R., Conti, S., Mannini, B., Li, X., Buxbaum, J. N., Tiribilli, B., Chiti, F., & Cecchi, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.011 · Cited by 86
Structure – Function Relationships of Pre-Fibrillar Protein Assemblies in Alzheimers Disease and Related Disorders
Rahimi, F., Shanmugam, A., & Bitan, G. (2008) · Current Alzheimer Research · doi:10.2174/156720508784533358 · Cited by 88
Microarray Analysis Identifies Changes in Inflammatory Gene Expression in Response to Amyloid-β Stimulation of Cultured Human Retinal Pigment Epithelial Cells
Kurji, K. H., Cui, J. Z., Lin, T. R., Harriman, D. I., Prasad, S. S., Kojic, L., & Matsubara, J. A. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3622 · Cited by 90
Disordered amyloidogenic peptides may insert into the membrane and assemble into common cyclic structural motifs
Jang, H., Arce, F. T., Ramachandran, S., Kagan, B. L., Lal, R., & Nussinov, R. (2014) · Chemical Society Reviews · doi:10.1039/c3cs60459d · Cited by 85
Membrane lipid composition and its physicochemical properties define cell vulnerability to aberrant protein oligomers
Evangelisti, E., Cecchi, C., Cascella, R., Sgromo, C., Becatti, M., Dobson, C. M., Chiti, F., & Stefani, M. (2012) · Journal of Cell Science · doi:10.1242/jcs.098434 · Cited by 84
Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases
Hickman, D. T., López-Deber, M. P., Ndao, D. M., Silva, A. B., Nand, D., Pihlgren, M., Giriens, V., Madani, R., St-Pierre, A., Karastaneva, H., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.186338 · Cited by 84
A protective role for lipid raft cholesterol against amyloid-induced membrane damage in human neuroblastoma cells
Cecchi, C., Nichino, D., Zampagni, M., Bernacchioni, C., Evangelisti, E., Pensalfini, A., Liguri, G., Gliozzi, A., Stefani, M., & Relini, A. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2009.07.019 · Cited by 82
Amyloid beta acts synergistically as a pro-inflammatory cytokine
LaRocca, T. J., Cavalier, A. N., Roberts, C. M., Lemieux, M. R., Ramesh, P., Garcia, M. A., & Link, C. D. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105493 · Cited by 83
Femtomole Immunodetection of Synthetic and Endogenous Amyloid-β Oligomers and Its Application to Alzheimer's Disease Drug Candidate Screening
Chang, L., Bakhos, L., Wang, Z., Venton, D. L., & Klein, W. L. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:305 · Cited by 81
Self-citation
Transthyretin Inhibits Primary and Secondary Nucleations of Amyloid-β Peptide Aggregation and Reduces the Toxicity of Its Oligomers
Ghadami, S. A., Chia, S., Ruggeri, F. S., Meisl, G., Bemporad, F., Habchi, J., Cascella, R., Dobson, C. M., Vendruscolo, M., Knowles, T. P. J., et al. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.9b01475 · Cited by 79
ADDLs & protofibrils —the missing links?
Klein, W. L. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00312-8 · Cited by 77
Self-citation
Screening for Inhibitors of Tau Polymerization
Pickhardt, M., von Bergen�, M., Gažová, Z., Hascher, A., Biernat, J., Mandelkow, E., & Mandelkow�, E. (2005) · Current Alzheimer Research · doi:10.2174/1567205053585891 · Cited by 74
3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain
Marutle, A., Gillberg, P.-G., Bergfors, A., Yu, W., Ni, R., Nennesmo, I., Voytenko, L., & Nordberg, A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-90 · Cited by 70
Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Aβ(1–42)☆
Rukhsana Sultana, A., Marzia Perluigi, A., & Butterfield, D. A. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.09.024 · Cited by 72
Conformation-sensitive Antibodies against Alzheimer Amyloid-β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide
Moretto, N., Bolchi, A., Rivetti, C., Imbimbo, B. P., Villetti, G., Pietrini, V., Polonelli, L., Signore, S. J. D., Smith, K. M., Ferrante, R. J., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609690200 · Cited by 69
Bildung von Peptidfibrillen
Hamley, I. W. (2007) · Angewandte Chemie · doi:10.1002/ange.200700861 · Cited by 69
Extracellular chaperones prevent Aβ42-induced toxicity in rat brains
Cascella, R., Conti, S., Tatini, F., Evangelisti, E., Scartabelli, T., Casamenti, F., Wilson, M. R., Chiti, F., & Cecchi, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.012 · Cited by 70
“Click Peptide“: pH‐Triggered in Situ Production and Aggregation of Monomer Aβ1–42
Taniguchi, A., Sohma, Y., Hirayama, Y., Mukai, H., Kimura, T., Hayashi, Y., Matsuzaki, K., & Kiso, Y. (2009) · ChemBioChem · doi:10.1002/cbic.200800765 · Cited by 68
Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease
Ding, Y. J., Zhao, J., Zhang, X., Wang, S., Viola, K. L., Chow, F. E., Zhang, Y., Lippa, C. F., Klein, W. L., & Gong, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01140 · Cited by 68
Self-citation
Reducing Cerebral Microvascular Amyloid-β Protein Deposition Diminishes Regional Neuroinflammation in Vasculotropic Mutant Amyloid Precursor Protein Transgenic Mice
Miao, J., Vitek, M. P., Xu, F., Previti, M. L., Davis, J., & Nostrand, W. E. V. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1306-05.2005 · Cited by 64
Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice
Sivilia, S., Lorenzini, L., Giuliani, A., Gusciglio, M., Fernández, M., Baldassarro, V. A., Mangano, C., Ferraro, L., Pietrini, V., Baroc, M. F., et al. (2013) · BMC Neuroscience · doi:10.1186/1471-2202-14-44 · Cited by 65
Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific
Zago, W., Buttini, M., Comery, T. A., Nishioka, C., Gardai, S. J., Seubert, P., Games, D., Bard, F., Schenk, D., & Kinney, G. G. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1676-11.2012 · Cited by 62
Targets for AD treatment: conflicting messages from γ-secretase inhibitors
Sambamurti, K., Greig, N. H., Utsuki, T., Barnwell, E., Sharma, E., Mazell, C., Bhat, N. R., Kindy, M. S., Lahiri, D. K., & Pappolla, M. A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07213.x · Cited by 62
The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells
Cai, W., Wu, T., & Chen, N. (2023) · Biomolecules · doi:10.3390/biom13020313 · Cited by 69
Conformation‐dependent single‐chain variable fragment antibodies specifically recognize beta‐amyloid oligomers
Wang, X.-P., Zhang, J.-H., Wang, Y.-J., Feng, Y. N., Zhang, X., Sun, X.-X., Li, J.-L., Du, X.-T., Lambert, M. P., Yang, S.-G., et al. (2009) · FEBS Letters · doi:10.1016/j.febslet.2008.12.064 · Cited by 62
Self-citation
Rhynchophylline suppresses soluble Aβ1-42-induced impairment of spatial cognition function via inhibiting excessive activation of extrasynaptic NR2B-containing NMDA receptors
Yang, Y., Ji, W.-G., Zhu, Z.-R., Wu, Y.-L., Zhang, Z., & Qu, S.-C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.03.007 · Cited by 62
Direct in Vivo Intracellular Selection of Conformation-sensitive Antibody Domains Targeting Alzheimer's Amyloid-β Oligomers
Meli, G., Visintin, M., Cannistraci, I., & Cattaneo, A. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.061 · Cited by 64
Tetrahydrocurcumin confers protection against amyloid β-induced toxicity
Mishra, S., Mishra, M., Seth, P., & Sharma, S. K. (2010) · Neuroreport · doi:10.1097/wnr.0b013e328341e141 · Cited by 61
Nanoscience enables ultrasensitive detection of Alzheimer's biomarker
Keating, C. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500024102 · Cited by 61
Small molecule inhibitors of Abetaassembly
LeVine, H. (2007) · Amyloid · doi:10.1080/13506120701461020 · Cited by 58
Antibody-based therapy in Alzheimer's disease
Pul, R., Dodel, R. C., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 59
Nanobody specific for oligomeric beta-amyloid stabilizes nontoxic form
Kasturirangan, S., Li, L., Emadi, S., Boddapati, S. P., Schulz, P., & Sierks, M. R. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.020 · Cited by 57
Amyloid-β Oligomer Specificity Mediated by the IgM Isotype – Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies
Lindhagen‐Persson, M., Brännström, K., Vestling, M., Steinitz, M. O., & Olofsson, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013928 · Cited by 57
Synapse-Binding Subpopulations of Aβ Oligomers Sensitive to Peptide Assembly Blockers and scFv Antibodies
Velasco, P. T., Heffern, M. C., Sebollela, A. S., Popova, I. A., Lacor, P. N., Lee, K. B., Sun, X., Tiano, B. N., Viola, K. L., Eckermann, A. L., et al. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300122k · Cited by 57
Self-citation
Soluble Oligomers Require a Ganglioside to Trigger Neuronal Calcium Overload
Cascella, R., Evangelisti, E., Bigi, A., Becatti, M., Fiorillo, C., Stefani, M., Chiti, F., & Cecchi, C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170340 · Cited by 57
Squalamine and Its Derivatives Modulate the Aggregation of Amyloid-β and α-Synuclein and Suppress the Toxicity of Their Oligomers
Limbocker, R., Staats, R., Chia, S., Ruggeri, F. S., Mannini, B., Xu, C. K., Perni, M., Cascella, R., Bigi, A., Sasser, L. R., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.680026 · Cited by 54
Polyphenolic Glycosides and Aglycones Utilize Opposing Pathways To Selectively Remodel and Inactivate Toxic Oligomers of Amyloid β
Ladiwala, A. R. A., Mora‐Pale, M., Lin, J. C., Bale, S. S., Fishman, Z. S., Dordick, J. S., & Tessier, P. M. (2011) · ChemBioChem · doi:10.1002/cbic.201100123 · Cited by 54
Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro
Xie, Z., Harris‐White, M. E., Wals, P. A., Frautschy, S. A., Finch, C. E., & Morgan, T. E. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03065.x · Cited by 53
Self-citation
Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons
Shughrue, P. J., Acton, P. J., Breese, R., Zhao, W., Chen-Dodson, E., Hepler, R. W., Wolfe, A. L., Matthews, M., Heidecker, G. J., Joyce, J. G., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.003 · Cited by 53
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecı̀ć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 54
Self-citation
Mitochondria in Aging and Alzheimer's Disease
Crouch, P. J., Cimdins, K., Duce, J. A., Bush, A. I., & Trounce, I. A. (2007) · Rejuvenation Research · doi:10.1089/rej.2007.0592 · Cited by 54
Expression and Localization of Mitochondrial Ferritin mRNA in Alzheimer's Disease Cerebral Cortex
Wang, L., Yang, H., Zhao, S., Sato, H., Konishi, Y., Beach, T. G., Abdelalim, E. M., Bisem, N. J., & Tooyama, I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022325 · Cited by 51
The Cu(II)/Aβ/Human Serum Albumin Model of Control Mechanism for Copper-Related Amyloid Neurotoxicity
Rózga, M., & Bal, W. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900358j · Cited by 54
Autoinsertion of soluble oligomers of Alzheimer's Abeta(1-42) peptide into cholesterol-containing membranes is accompanied by relocation of the sterol towards the bilayer surface.
Ashley, R. H., Harroun, T. A., Hauß, T., Breen, K. C., & Bradshaw, J. P. (2006) · BMC Structural Biology · doi:10.1186/1472-6807-6-21 · Cited by 52
A review on protein misfolding, aggregation and strategies to prevent related ailments
Shamsi, T. N., Athar, T., Parveen, R., & Fatima, S. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.07.116 · Cited by 56
The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model
Ostrovskaya, R. U., Алексеевна, Г. М., Bobkova, N. A., Sewell, R. D. E., Гудашева, Т. А., Samokhin, A. N., Seredinin, S. B., Noppe, W., Sherstnev, V. V., & Morozova‐Roche, L. A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106071335 · Cited by 55
An ultra‐sensitive immunoassay detects and quantifies soluble Aβ oligomers in human plasma
Liu, L., Kwak, H., Lawton, T., Jin, S., Meunier, A. L., Dang, Y., Ostaszewski, B. L., Pietras, A., Stern, A. M., & Selkoe, D. J. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12457 · Cited by 49
Development and validation of a yeast high-throughput screen for inhibitors of Aβ42 oligomerization
Park, S.-K., Pegan, S. D., Mesecar, A. D., Jungbauer, L. M., LaDu, M. J., & Liebman, S. W. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.007963 · Cited by 50
Single Chain Fv Antibodies against the 25−35 Aβ Fragment Inhibit Aggregation and Toxicity of Aβ42
Zameer, A., Schulz, P., Wang, M. S., & Sierks, M. R. (2006) · Biochemistry · doi:10.1021/bi060601o · Cited by 48
Solution NMR Studies of Recombinant Aβ(1–42): From the Presence of a Micellar Entity to Residual β‐Sheet Structure in the Soluble Species
Wälti, M. A., Orts, J., Vögeli, B., Campioni, S., & Riek, R. (2015) · ChemBioChem · doi:10.1002/cbic.201402595 · Cited by 49
Synthetic dityrosine-linked β-amyloid dimers form stable, soluble, neurotoxic oligomers
Kok, W. M., Cottam, J. M., Ciccotosto, G. D., Miles, L. A., Karas, J. A., Scanlon, D. B., Roberts, B. R., Parker, M. W., Cappai, R., Barnham, K. J., et al. (2013) · Chemical Science · doi:10.1039/c3sc22295k · Cited by 46
Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers
Kreiser, R. P., Wright, A. K., Block, N. R., Hollows, J. E., Nguyen, L. T., LeForte, K., Mannini, B., Vendruscolo, M., & Limbocker, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228651 · Cited by 48
Heavy-Chain Complementarity-Determining Regions Determine Conformation Selectivity of Anti-Aβ Antibodies
Sehlin, D., Hedlund, M., Lord, A., Englund, H., Gellerfors, P., Paulie, S., Lannfelt, L., & Pettersson, F. E. (2010) · Neurodegenerative Diseases · doi:10.1159/000316530 · Cited by 47
Probing the origins, diagnosis and treatment of amyloid diseases using antibodies
Dumoulin, M., & Dobson, C. M. (2004) · Biochimie · doi:10.1016/j.biochi.2004.09.012 · Cited by 45
Identification of a Mutant Amyloid Peptide That Predominantly Forms Neurotoxic Protofibrillar Aggregates
Qahwash, I. M., Weiland, K. L., Lu, Y., Sarver, R. W., Kletzien, R. F., & Yan, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213298200 · Cited by 45
Neuronal and Axonal Loss Are Selectively Linked to Fibrillar Amyloid-β within Plaques of the Aged Primate Cerebral Cortex
Shah, P., Lal, N., Leung, E., Traul, D., Gonzalo‐Ruiz, A., & Geula, C. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090937 · Cited by 48
Amyloid-β Oligomers: Multiple Moving Targets
Shea, D. W., & Daggett, V. (2022) · Biophysica · doi:10.3390/biophysica2020010 · Cited by 43
Characterisation of two antibodies to oligomeric Aβ and their use in ELISAs on human brain tissue homogenates
Helmond, Z. V., Heesom, K. J., & Love, S. (2008) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2008.09.002 · Cited by 44
Genetic Alterations of the BRI2 gene: Familial British and Danish Dementias
J, G., A, R., Y, T., T, L., M, B.-M., H, B., G, P., J, H., R, L., T, R., et al. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2006.tb00563.x · Cited by 44
Persistent sodium currents contribute to Aβ1-42-induced hyperexcitation of hippocampal CA1 pyramidal neurons
Ren, S., Chen, P.-Z., Jiang, H., Mi, Z., Xu, F., Hu, B., Zhang, J., & Zhu, Z.-R. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.07.050 · Cited by 43
PGH2‐derived levuglandin adducts increase the neurotoxicity of amyloid β1–42
Boutaud, O. G., Montine, T. J., Chang, L., Klein, W. L., & Oates, J. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03586.x · Cited by 44
Self-citation
Misfolded protein oligomers induce an increase of intracellular Ca2+ causing an escalation of reactive oxidative species
Fani, G., Torre, C. E. L., Cascella, R., Cecchi, C., Vendruscolo, M., & Chiti, F. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04513-w · Cited by 44
Membrane cholesterol enrichment prevents Aβ-induced oxidative stress in Alzheimer's fibroblasts
Pensalfini, A., Zampagni, M., Liguri, G., Becatti, M., Evangelisti, E., Fiorillo, C., Bagnoli, S., Cellini, E., Nacmias, B., Sorbi, S., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.010 · Cited by 43
Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
Rocha, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990613 · Cited by 42
In vivo induction of membrane damage by β-amyloid peptide oligomers
Julien, C., Tomberlin, C., Roberts, C. M., Akram, A., Stein, G. H., Silverman, M. A., & Link, C. D. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0634-x · Cited by 39
Design and Optimization of Anti-amyloid Domain Antibodies Specific for β-Amyloid and Islet Amyloid Polypeptide
Lee, C. C., Julian, M. C., Tiller, K. E., Meng, F., DuConge, S. E., Akter, R., Raleigh, D. P., & Tessier, P. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.682336 · Cited by 41
A glycine zipper motif mediates the formation of toxic β-amyloid oligomers in vitro and in vivo
Fonte, V. G., Dostal, V., Roberts, C. M., Gonzales, P. K., Lacor, P. N., Magrané, J., Dingwell, N., Fan, E. Y., Silverman, M. A., Stein, G. H., et al. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-61 · Cited by 37
Microglia activation mediates fibrillar amyloid-β toxicity in the aged primate cortex
Leung, E., Guo, L., Bu, J., Maloof, M. E., Khoury, J. B. E., & Geula, C. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.025 · Cited by 40
Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid β-protein and GM-CSF
Kim, H., Cao, Y., Kong, F.-K., Kampen, K. R. V., Lewis, T. L., Ma, Z., Tang, D.-C. C., & Fukuchi, K.-I. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.12.015 · Cited by 39
Is there a future for vaccination as a treatment for Alzheimer's disease?
McGeer, P. L. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00157-4 · Cited by 39
Advances on the Understanding of the Origins of Synaptic Pathology in AD
Lacor, P. N. (2007) · Current Genomics · doi:10.2174/138920207783769530 · Cited by 40
Plasma Membrane Injury Depends on Bilayer Lipid Composition in Alzheimer's Disease
Evangelisti, E., Zampagni, M., Cascella, R., Becatti, M., Fiorillo, C., Caselli, A., Bagnoli, S., Nacmias, B., & Cecchi, C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131406 · Cited by 37
Overcoming synthetic Aβ peptide aging: a new approach to an age-old problem
Manzoni, C., Colombo, L., Messa, M., Cagnotto, A., Cantú, L., Favero, E. D., & Salmona, M. (2009) · Amyloid · doi:10.1080/13506120902879848 · Cited by 37
Per-6-substituted-per-6-deoxy β-cyclodextrins Inhibit the Formation of β-Amyloid Peptide Derived Soluble Oligomers
Wang, Z., Chang, L., Klein, W. L., Thatcher, G. R. J., & Venton, D. L. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm034224e · Cited by 37
Self-citation
Cystatin C colocalizes with amyloid‐β and coimmunoprecipitates with amyloid‐β precursor protein in sporadic inclusion‐body myositis muscles
Vattemi, G. N. A., Engel, W. K., McFerrin, J., & Askanas, V. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01798.x · Cited by 37
Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding
Bateman, D. A., McLaurin, J., & Chakrabartty, A. (2007) · BMC Neuroscience · doi:10.1186/1471-2202-8-29 · Cited by 36
The expression of p75 neurotrophin receptor protects against the neurotoxicity of soluble oligomers of β-amyloid
Costantini, C., Bianca, V. D., Formaggio, E., Chiamulera, C., Montresor, A., & Rossi, F. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.09.004 · Cited by 36
A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid‐β oligomers
Sebollela, A. S., Cline, E. N., Popova, I. A., Luo, K., Sun, X., Ahn, J., Barcelos, M. A., Bezerra, V. N., Silva, N. M. L. E., Patel, J., et al. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14118 · Cited by 38
Self-citation
Molecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease
Żukowska, J., Moss, S. J., Subramanian, V., & Acharya, K. R. (2023) · FEBS Journal · doi:10.1111/febs.16939 · Cited by 36
Nanoscale Synaptic Membrane Mimetic Allows Unbiased High Throughput Screen That Targets Binding Sites for Alzheimer’s-Associated Aβ Oligomers
Wilcox, K. C., Marunde, M. R., Das, A., Velasco, P. T., Kuhns, B. D., Marty, M. T., Haoming, J., Luan, C.-H., Sligar, S. G., & Klein, W. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125263 · Cited by 37
Self-citation
Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse
Takamura, A., Okamoto, Y., Kawarabayashi, T., Yokoseki, T., Shibata, M. S., Mouri, A., Nabeshima, T., Sun, H., Abe, K., Urisu, T., et al. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-20 · Cited by 34
Soluble amyloid β oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma
Yin, H., Chen, L., Chen, X., & Liu, X. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.01.030 · Cited by 34
Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin
Wang, T., Xie, X.-X., Ji, M., Wang, S., Zha, J., Zhou, W.-W., Yu, X., Chen, W., Ma, S., Xi, Z.-Y., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.015 · Cited by 34

Authors: Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., & Klein, W. L.
Affiliations: Northwestern University (US)
University of Southern California (US)
University of Illinois Chicago (US)
Corresponding author: Klein, William L.
ORCID: Viola, Kirsten L.
Chang, Lei
Morgan, Todd E.
Yu, Jiaxin
Finch, Caleb E.
Klein, William L.
Venue: Journal of Neurochemistry
Publisher: Wiley
Published: 2001-11
Volume: 79
Issue: 3
Pages: 595-605
ISSN: 0022-3042 (ISSN-L)
1471-4159
DOI: 10.1046/j.1471-4159.2001.00592.x
OpenAlex: W1857351893
Cited by: 349
References: 45
Citations by year: 2026: 12 · 2025: 8 · 2024: 4 · 2023: 11 · 2022: 6 · 2021: 8 · 2020: 15 · 2019: 10 · 2018: 5 · 2017: 11 · 2016: 6 · 2015: 10 · 2014: 18 · 2013: 20 · 2012: 20
FWCI: 8.37
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2440 d)
Locations: Journal of Neurochemistry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
National Institute on Aging (AG-13499, P01 AG13138, R01AG013499)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Alzheimer's disease, amyloid-beta oligomers, amyloid-beta 42, immunization, neutralizing antibodies, amyloid plaques, amyloid protofibrils, oligomer toxicity, Alzheimer's disease vaccine, transgenic mice
MeSH terms: Alzheimer Disease, Animals, Antibody Specificity, Epitopes, Fluorescent Antibody Technique, Hippocampus, Humans, Neurons, Peptide Fragments, Solubility, Vaccination, Amyloid beta-Peptides, PC12 Cells, Neuroprotective Agents, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks